Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immuneering Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IMRX
Nasdaq
8731
https://immuneering.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immuneering Corp
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Mar 27th, 2024 12:00 pm
Immuneering Director Acquires 7.5% More Stock
- Mar 21st, 2024 10:41 am
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
- Mar 18th, 2024 3:02 pm
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- Mar 14th, 2024 11:00 am
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
- Mar 12th, 2024 12:00 pm
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
- Mar 11th, 2024 12:00 pm
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
- Mar 5th, 2024 10:00 pm
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
- Mar 4th, 2024 1:00 pm
Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results
- Mar 4th, 2024 12:01 am
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Mar 1st, 2024 1:00 pm
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
- Feb 20th, 2024 1:00 pm
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave
- Feb 14th, 2024 8:45 pm
Immuneering Announces Participation in February Investor Conferences
- Feb 1st, 2024 1:00 pm
With 37% ownership, Immuneering Corporation (NASDAQ:IMRX) has piqued the interest of institutional investors
- Jan 9th, 2024 11:38 am
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Dec 12th, 2023 1:00 pm
Here's Why We're Watching Immuneering's (NASDAQ:IMRX) Cash Burn Situation
- Nov 29th, 2023 11:47 am
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
- Nov 20th, 2023 9:05 pm
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Nov 9th, 2023 9:05 pm
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
- Oct 12th, 2023 8:05 pm
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Oct 4th, 2023 8:05 pm
Scroll